Showing 1 - 7 results of 7 for search 'Aria Shokoohi', query time: 0.03s Refine Results
  1. 1
    Real world duration of curative intent breast, colorectal, non-small cell lung, and prostate cancer treatment

    Real world duration of curative intent breast, colorectal, non-small cell lung, and prostate cancer treatment by Selina K. Wong, Jeremy Hamm, Aria Shokoohi, Colleen E. McGahan, Cheryl Ho

    Published 2021-03-01
    Get full text
    Article
  2. 2
    Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy

    Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy by Rebekah Rittberg, Bonnie Leung, Aria Shokoohi, Alexandra Pender, Selina Wong, Zamzam Al-Hashami, Ying Wang, Cheryl Ho

    Published 2023-05-01
    Get full text
    Article
  3. 3
    Alternate Pembrolizumab Dosing Interval in Advanced NSCLC with PD-L1 TPS ≥ 50%: 3 Weekly Compared to 6 Weekly Dosing

    Alternate Pembrolizumab Dosing Interval in Advanced NSCLC with PD-L1 TPS ≥ 50%: 3 Weekly Compared to 6 Weekly Dosing by Lauren Jones, Rebekah Rittberg, Bonnie Leung, Aria Shokoohi, Alexandra Pender, Selina Wong, Zamzam Al-Hashami, Ying Wang, Cheryl Ho

    Published 2022-11-01
    Get full text
    Article
  4. 4
    Improved uptake and survival with systemic treatments for metastatic non-small cell lung cancer: younger versus older adults

    Improved uptake and survival with systemic treatments for metastatic non-small cell lung cancer: younger versus older adults by Bonnie Leung, Aria Shokoohi, Zamzam Al-Hashami, Sara Moore, Alexandra Pender, Selina K. Wong, Ying Wang, Jonn Wu, Cheryl Ho

    Published 2023-04-01
    Get full text
    Article
  5. 5
    Beyond PACIFIC: Real-World Outcomes of Adjuvant Durvalumab According to Treatment Received and PD-L1 Expression

    Beyond PACIFIC: Real-World Outcomes of Adjuvant Durvalumab According to Treatment Received and PD-L1 Expression by Marie-Hélène Denault, Jamie Feng, Shelley Kuang, Aria Shokoohi, Bonnie Leung, Mitchell Liu, Eric Berthelet, Janessa Laskin, Sophie Sun, Tina Zhang, Cheryl Ho, Barbara Melosky

    Published 2023-08-01
    Get full text
    Article
  6. 6
    Comparison of 2-Weekly Versus 4-Weekly Durvalumab Consolidation for Locally Advanced NSCLC Treated With Chemoradiotherapy: A Brief Report

    Comparison of 2-Weekly Versus 4-Weekly Durvalumab Consolidation for Locally Advanced NSCLC Treated With Chemoradiotherapy: A Brief Report by Marie-Hélène Denault, MD, MSc, Shelley Kuang, MD, FRCPC, Aria Shokoohi, BSc, Bonnie Leung, MN-NP, Mitchell Liu, MDCM, FRCPC, Eric Berthelet, MD, FRCPC, Janessa Laskin, MD, FRCPC, Sophie Sun, MD, FRCPC, Tina Zhang, MD, FRCPC, Barbara Melosky, MD, FRCPC, Cheryl Ho, MD, FRCPC

    Published 2022-05-01
    Get full text
    Article
  7. 7
    The economic value of liquid biopsy for genomic profiling in advanced non-small cell lung cancer

    The economic value of liquid biopsy for genomic profiling in advanced non-small cell lung cancer by Doreen A. Ezeife, Eldon Spackman, Rosalyn A. Juergens, Janessa J. Laskin, Jason S. Agulnik, Desiree Hao, Scott A. Laurie, Jennifer H. Law, Lisa W. Le, Lesli A. Kiedrowski, Barbara Melosky, Frances A. Shepherd, Victor Cohen, Paul Wheatley-Price, Rachel Vandermeer, Janice J. Li, Roxanne Fernandes, Aria Shokoohi, Richard B. Lanman, Natasha B. Leighl

    Published 2022-07-01
    Get full text
    Article

Search Tools: